Vitamin D Testing
APAC
Medical Devices
APAC
APAC Breast Pumps Market Analysis, 2024–2034
Updated
Reviewed by Vidhi Upadhyay
Updated
Reviewed by Vidhi Upadhyay
APAC Breast Pumps Market Industry Trends and Forecast to 2034: Segmented by (Product, Use, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$789.0 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $598.1 Mn | — | — |
| 2025 (base) | $653.1 Mn | +$55.0 Mn | — |
| 2026 (forecast) | $713.2 Mn | +$60.1 Mn | +9.2% |
| 2027 (forecast) | $778.8 Mn | +$65.6 Mn | +19.2% |
| 2028 (forecast) | $850.5 Mn | +$71.7 Mn | +30.2% |
| 2029 (forecast) | $928.7 Mn | +$78.2 Mn | +42.2% |
| 2030 (forecast) | $1.01 Bn | +$85.4 Mn | +55.3% |
| 2031 (forecast) | $1.11 Bn | +$93.3 Mn | +69.6% |
| 2032 (forecast) | $1.21 Bn | +$101.9 Mn | +85.2% |
| 2033 (forecast) | $1.32 Bn | +$111.3 Mn | +102.2% |
| 2034 (forecast) | $1.44 Bn | +$121.5 Mn | +120.8% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
US
$1.49 Bn
Canada
$251.7 Mn
China
$257.7 Mn
Japan
$185.9 Mn
Germany
$125.5 Mn
France
$91.2 Mn
Brazil
$89.2 Mn
UK
$74.1 Mn
Ecuador
$74.3 Mn
Italy
$70.4 Mn
Spain
$68.0 Mn
India
$61.9 Mn
Saudi Arabia
$56.8 Mn
Mexico
$46.8 Mn
Australia
$39.0 Mn
New Zealand
$33.8 Mn
Russia
$33.0 Mn
South Africa
$25.7 Mn
UAE
$14.7 Mn
Egypt
$11.0 Mn
Philippines
$7.5 Mn
Malaysia
$5.8 Mn
Hong Kong
$5.3 Mn
Singapore
$4.3 Mn
Thailand
$4.1 Mn
Kenya
$2.1 Mn
| Market size, 2025 | $653.1 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $1.44 Bn placeholder estimate |
| Growth (CAGR), 2025–2034 | 9.2% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Product, use and end user (see all) |
| Key players | Medela, Elvie (Chiaro), Willow Innovations, Philips Avent, Lansinoh and 1 more (see all) |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Breast pumps help mothers express breast milk, with manual, electric and wearable models for home and hospital use.
Key segments of the breast Pumps market include product (Wearable Pumps, Electric Pumps and Manual Pumps) and use (Personal Use, Hospital Use and Rental).
Greater awareness of women's health needs, more funding for female-focused research, later pregnancies and an ageing female population are driving the breast Pumps market. New products designed around women's biology and digital care are improving access.
Femtech, personalised care and new treatments for under-served conditions open strong growth for the breast Pumps market, especially as employers and payers add women's health benefits.
Under-diagnosis, stigma around some conditions, limited insurance coverage and a long history of under-research in women's health hold back the breast Pumps market.
The breast Pumps market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
In some of the countries we cover here, medical devices are regulated by TGA (Australia)[1], NMPA (China)[2], MDACS (Hong Kong)[3], CDSCO (India)[4], PMDA (Japan)[5], MDA (Malaysia)[6], Medsafe (WAND) (New Zealand)[7], FDA Philippines (Philippines)[8], HSA (Singapore)[9] and Thai FDA (Thailand)[10]. How care is paid for in some of these countries: Medicare and the PBS (Australia)[11], basic medical insurance (China)[12], the Hospital Authority (Hong Kong)[13], Ayushman Bharat PM-JAY (India)[14], public health insurance (Japan)[15], subsidised public care (Malaysia)[16], Pharmac (New Zealand)[17], PhilHealth (Philippines)[18], MediShield Life (Singapore)[19] and the Universal Coverage Scheme (Thailand)[20].
[1] Therapeutic Goods Administration. Checked 14 Nov 2026.
[2] National Medical Products Administration. Checked 14 Nov 2026.
[3] Medical Device Division, Department of Health. Checked 14 Nov 2026.
[4] Central Drugs Standard Control Organisation. Checked 14 Nov 2026.
[5] Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.
[6] Medical Device Authority. Checked 14 Nov 2026.
[7] Medsafe. Checked 14 Nov 2026.
[8] Food and Drug Administration Philippines. Checked 14 Nov 2026.
[9] Health Sciences Authority. Checked 14 Nov 2026.
[10] Thai Food and Drug Administration. Checked 14 Nov 2026.
[11] Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.
[12] National Healthcare Security Administration. Checked 14 Nov 2026.
[13] Hospital Authority. Checked 14 Nov 2026.
[14] National Health Authority (PM-JAY). Checked 14 Nov 2026.
[15] Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.
[16] Ministry of Health Malaysia. Checked 14 Nov 2026.
[17] Pharmac. Checked 14 Nov 2026.
[18] PhilHealth. Checked 14 Nov 2026.
[19] CPF Board, MediShield Life. Checked 14 Nov 2026.
[20] National Health Security Office. Checked 14 Nov 2026.
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how breast Pumps products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in APAC.
What doctors and scientists are doing in Breast Pumps right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
From our blog
Pharmaceuticals · APAC
Healthcare Services · APAC
Pharmaceuticals · APAC
Pharmaceuticals · APAC
Pharmaceuticals · APAC
Healthcare Services · APAC